Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$154.35
-1.8%
$140.70
$91.86
$254.15
$7.58B1.491.03 million shs211,315 shs
Icon Plc stock logo
ICLR
Icon
$147.42
-1.8%
$139.88
$125.10
$347.72
$11.89B1.171.10 million shs480,118 shs
PPD, Inc. stock logo
PPD
PPD
$47.28
$47.27
$31.54
$47.41
$16.61B1.961.91 million shsN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$165.21
$167.50
$93.00
$175.95
$10.70B1.31837,472 shs57 shs
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
$42.86
$22.89
$52.23
$4.46B1.581.92 million shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%+4.81%+8.56%+17.28%-21.31%
Icon Plc stock logo
ICLR
Icon
0.00%+3.80%+7.87%-0.51%-53.22%
PPD, Inc. stock logo
PPD
PPD
0.00%0.00%0.00%0.00%0.00%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00%0.00%0.00%0.00%0.00%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.0764 of 5 stars
2.12.00.04.72.42.51.9
Icon Plc stock logo
ICLR
Icon
4.3634 of 5 stars
4.33.00.00.01.83.32.5
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.19
Hold$171.8511.33% Upside
Icon Plc stock logo
ICLR
Icon
2.60
Moderate Buy$213.0844.54% Upside
PPD, Inc. stock logo
PPD
PPD
0.00
N/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00
N/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CRL, ICLR, SYNH, PPD, and PRAH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/15/2025
Icon Plc stock logo
ICLR
Icon
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $173.00
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$179.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$170.00
5/2/2025
Icon Plc stock logo
ICLR
Icon
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $155.00
5/2/2025
Icon Plc stock logo
ICLR
Icon
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $160.00
5/2/2025
Icon Plc stock logo
ICLR
Icon
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$192.00 ➝ $160.00
4/29/2025
Icon Plc stock logo
ICLR
Icon
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$265.00 ➝ $150.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.87$21.32 per share7.24$67.80 per share2.28
Icon Plc stock logo
ICLR
Icon
$8.19B1.45$19.68 per share7.49$117.92 per share1.25
PPD, Inc. stock logo
PPD
PPD
$4.68B3.55$1.99 per share23.71($1.21) per share-39.07
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$3.18B3.36$6.09 per share27.11$23.06 per share7.16
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.035.32-0.66%15.19%6.93%8/6/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.1816.049.641.849.25%11.46%6.49%7/23/2025 (Estimated)
PPD, Inc. stock logo
PPD
PPD
$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$197.04M$3.9050.5226.31N/A6.40%20.49%7.07%N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A

Latest CRL, ICLR, SYNH, PPD, and PRAH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18N/AN/AN/A$1.98 billionN/A
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
4/30/2025Q1 2025
Icon Plc stock logo
ICLR
Icon
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Icon Plc stock logo
ICLR
Icon
0.36
1.27
1.27
PPD, Inc. stock logo
PPD
PPD
N/A
1.23
1.23
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.74
1.21
1.21
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%
PPD, Inc. stock logo
PPD
PPD
87.82%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
93.93%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
91.16%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
PPD, Inc. stock logo
PPD
PPD
1.90%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
1.30%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
PPD, Inc. stock logo
PPD
PPD
26,000351.40 million344.72 millionNot Optionable
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
18,10064.80 millionN/AOptionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable

Recent News About These Companies

The Escalator: Syneos Health, The FDA, Pfizer and more
Syneos Health makes senior hires
Syneos Health Gets Worker Claims Trimmed in Vaccine Bias Lawsuit
INC Research/inVentiv Health Becomes Syneos Health
Investment group will take Syneos Health private
Hayward Holdings, Inc. (HAYW)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$154.35 -2.77 (-1.76%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$147.42 -2.68 (-1.79%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

PPD stock logo

PPD NASDAQ:PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

PRA Health Sciences stock logo

PRA Health Sciences NASDAQ:PRAH

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Syneos Health stock logo

Syneos Health NASDAQ:SYNH

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.